We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Hand-Held Biosensor Device Could Enable Immediate, Sensitive Point-of-Care Detection of SARS-CoV-2 from Saliva

By LabMedica International staff writers
Posted on 02 Feb 2021
A handheld biosensor that instantaneously detects viruses and disease in saliva could revolutionize point-of-care (POC) COVID-19 testing.

Blink Science, Inc. More...
(Jacksonville, FL, USA) will soon bring to market, blinkTEST, a handheld biosensor device that can immediately detect COVID-19, and other disease biomarkers in saliva. Most POC testing devices currently available, or that have received Emergency Use Authorization (EUA), provide tests in well over 20-30 minutes. Blink is developing a low-cost, high-tech device that will provide an immediate testing response. The system will provide health reports that can be analyzed immediately to ensure rapid and precise diagnosis for acute and chronic conditions that impact people worldwide. blinkTEST will give instantaneous results without requiring costly genetic testing.

The blinkTEST biosensor reads the electrical charges between antibodies and an easy-to use test strip. And while the initial usages will be to combat COVID-19, the technology has also been tested in the lab with extremely low concentrations of proteins secreted during myocardial infarcts (heart attacks) and to detect cerebrospinal fluid, indicating that this novel testing approach could be applied to a broad set of existing diagnostic. The unique test strips will be capable of molecular detection of antigen-antibody binding and can deliver qualitative and, in some cases, highly sensitive quantitative data.

The modular technology platform will be capable of testing for multiple infectious agents (viral, bacterial, and parasitic), disease-related proteins (cardiac disease and potentially cancer), and chemicals (substance abuse or environmental contaminants) within or external to the body using saliva, urine, blood, or other biological samples. This fundamental breakthrough in bioelectronic molecular testing is instant, reliable, inexpensive (pennies per strip), ultra-sensitive (ng/ml), highly specific, and portable. The product is not yet currently available for use in the US and is in the preparation phase of being submitted to the FDA for an EUA.

“What we are bringing to market is revolutionary. This device will be able to provide the fastest test not only for COVID-19, but also for a number of other viruses and specific disease states” said Blink Science CEO and president, Eric Doherty.

Related Links:
Blink Science, Inc.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Portable Electronic Pipette
Mini 96
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The nanotechnology-based liquid biopsy test could identify cancer at its early stages (Photo courtesy of 123RF)

2-Hour Cancer Blood Test to Transform Tumor Detection

Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.